TITLE

PROSPECTIVE 2 YEAR STUDY OF 5-AMINOSALICYATE NEPHROTOXICITY IN THE UK

AUTHOR(S)
Muller, A. F.; Stevens, P. E.; McIntyre, A. S.; Ellison, J. H.; Logan, R. F.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The 2 year prospective study assessed the epidemiology at nephrotoxicity associated with 5-amino-salicylate (5-ASA) use in patients with inflammatory bowel disease (IBD) in Great Britain, from January 2000 to December 2002. The 1298 names in the British Society of Gastroenterology database reported new cases on a monthly basis. All 290 consultant members of the Renal Association reported cases every 6 months. Nephrotoxicity is a serious complication at 5-ASA therapy. Regular monitoring of renal function during treatment may allow earlier detection, particularly during the first year of therapy. Based on an IBD prevalence in the nation of 412/10 with 1-50% on treatment, researchers estimate that clinical nephrotoxicity occurs in about 1 in 4000 patients/year taking 5-ASA therapy.
ACCESSION #
13218820

 

Related Articles

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Medical management of inflammatory bowel disease. Morris, David // Independent Nurse;3/2/2009, p27 

    The article features the implication and treatment of inflammatory bowel disease (IBD) in Great Britain. The said illness comprises of Crohn's disease (CD) and ulcerative colitis (UC), characterised by inflammation of the gut mucosa. Ways of treating the disease include intravenous steroid...

  • Selective Adhesion-Molecule Therapy and Inflammatory Bowel Disease – A Tale of Janus? Podolsky, Daniel K. // New England Journal of Medicine;11/3/2005, Vol. 353 Issue 18, p1965 

    This article discusses various issues related to selective adhesion-molecule therapy and inflammatory bowel disease, with specific reference to certain researches conducted in this regard. Two early studies suggested that natalizumab had an effect in patients with Crohn's disease, but the...

  • Second Annual Snowbird Conference on Clinical Management of Inflammatory Bowel Diseases and Intestinal Failure March 9—12, 2006. Buchman, Alan L. // American Journal of Gastroenterology;Jun2007 Supplement, Vol. 102, pS1 

    Information about the clinical management of inflammatory bowel disease (IBD) and intestinal failure which was discussed during the Second Annual Snowbird Conference on March 9-12, 2006 in Utah is presented. The incidence of IBD, such as Crohn's disease and ulcerative colitis, and intestinal...

  • The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn’s disease. Tamaki, Hiroyuki; Nakase, Hiroshi; Matsuura, Minoru; Inoue, Satoko; Mikami, Sakae; Ueno, Satoru; Uza, Norimitsu; Kitamura, Hiroshi; Kasahara, Katsuhiro; Chiba, Tsutomu // Journal of Gastroenterology;2008, Vol. 43 Issue 10, p774 

    Recent evidence indicates that intravenous or oral therapy with tacrolimus (FK-506) is effective in treating patients with Crohn’s disease. We evaluated the usefulness of tacrolimus therapy for Japanese patients with refractory Crohn’s disease. Fourteen adult Japanese patients with...

  • Exploring life before IBD. De Vroey, Bénédicte; Gower-Rousseau, Corinne; Colombel, Jean-Frédéric // Gut;May2013, Vol. 62 Issue 5, p662 

    The authors discuss the aspect of serological markers as predictors of inflammatory bowel disease (IBD). They indicate that treatment goals are evolving in IBD from symptoms control towards prevention of bowel damage. They reveal that about a third of patients with Crohn's disease (CD) still...

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Inflammatory Bowel Diseases: Advances in Treatment, Causes. Wilson, Kenneth H. // DukeMedicine HealthNews;Feb2012, Vol. 18 Issue 2, p4 

    The article discusses the causes and treatment of inflammatory bowel diseases (IBD) which composed of two related but different diseases such as the Crohn's disease (CD) and ulcerative colitis (UC). The diseases are characterized by chronic and spontaneous inflammation, and can affect any part...

  • Meta-analysis: rapid infliximab infusions are safe. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p21 

    The article presents a study that examines the safety of infliximab infusions in patients with inflammatory bowel disease (IBD). It describes the method of the study that uses the meta-analysis and evaluates the infusion reaction in patients given with rapid infusion. It also notes the findings...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics